AR035137A1 - PHARMACEUTICAL COMPOSITION TO INHIBIT METASTASIS OR PREVENT RECURRENCE OF EVIL TUMOR - Google Patents

PHARMACEUTICAL COMPOSITION TO INHIBIT METASTASIS OR PREVENT RECURRENCE OF EVIL TUMOR

Info

Publication number
AR035137A1
AR035137A1 ARP020103077A ARP020103077A AR035137A1 AR 035137 A1 AR035137 A1 AR 035137A1 AR P020103077 A ARP020103077 A AR P020103077A AR P020103077 A ARP020103077 A AR P020103077A AR 035137 A1 AR035137 A1 AR 035137A1
Authority
AR
Argentina
Prior art keywords
group
formula
active ingredient
pharmaceutical composition
possesses
Prior art date
Application number
ARP020103077A
Other languages
Spanish (es)
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR035137A1 publication Critical patent/AR035137A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Una composición farmacéutica para inhibir metástasis o prevenir la recurrencia de un tumor maligno, que comprende como ingrediente activo un derivado de polisacárido que comprende un polisacárido que posee un grupo carboxilo unido a un ingrediente activo que posee una actividad antitumor por medio de un aminoácido o un péptido de 2 a 8 aminoácidos que son iguales o diferentes, o una sal del mismo. Preferentemente, el ingrediente activo que posee una actividad antitumor es un derivado de camptotecina de la fórmula (1) en donde R1 es un grupo alquilo inferior sustituido o sin sustituir; X1 es un grupo de la fórmula: -NHR2 (R2 es un átomo de hidrógeno o un grupo alquilo inferior) y Alk es un grupo alquileno C1-6 de cadena lineal o cadena ramificada que opcionalmente posee un átomo de oxígeno en la cadena del mismo, o un compuesto de la fórmula (2) en donde dos grupos de R2 a R6 que son adyacentes entre sí se combinan para formar un grupo alquileno inferior, y uno de los átomos del carbono de dicho grupo alquileno inferior es sustituido por un grupo amino, y los tres grupos de R2 a R6 restantes son un átomo de hidrógeno, un grupo alquilo inferior o un átomo de halógeno.A pharmaceutical composition for inhibiting metastasis or preventing the recurrence of a malignant tumor, comprising as active ingredient a polysaccharide derivative comprising a polysaccharide that has a carboxyl group attached to an active ingredient that possesses an antitumor activity by means of an amino acid or a peptide of 2 to 8 amino acids that are the same or different, or a salt thereof. Preferably, the active ingredient that possesses an antitumor activity is a camptothecin derivative of the formula (1) wherein R1 is a substituted or unsubstituted lower alkyl group; X1 is a group of the formula: -NHR2 (R2 is a hydrogen atom or a lower alkyl group) and Alk is a C1-6 straight chain or branched chain alkylene group that optionally possesses an oxygen atom in the chain thereof , or a compound of the formula (2) wherein two groups of R2 to R6 that are adjacent to each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group , and the remaining three groups of R2 to R6 are a hydrogen atom, a lower alkyl group or a halogen atom.

ARP020103077A 2001-08-21 2002-08-15 PHARMACEUTICAL COMPOSITION TO INHIBIT METASTASIS OR PREVENT RECURRENCE OF EVIL TUMOR AR035137A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21

Publications (1)

Publication Number Publication Date
AR035137A1 true AR035137A1 (en) 2004-04-14

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103077A AR035137A1 (en) 2001-08-21 2002-08-15 PHARMACEUTICAL COMPOSITION TO INHIBIT METASTASIS OR PREVENT RECURRENCE OF EVIL TUMOR

Country Status (18)

Country Link
EP (1) EP1418947A1 (en)
KR (1) KR20040027972A (en)
CN (1) CN100372570C (en)
AR (1) AR035137A1 (en)
AU (1) AU2002328093B2 (en)
BR (1) BR0212036A (en)
CA (1) CA2457056C (en)
HU (1) HUP0401351A3 (en)
IL (1) IL160148A0 (en)
MX (1) MXPA04001599A (en)
NO (1) NO20041194L (en)
NZ (1) NZ530947A (en)
PL (1) PL368319A1 (en)
RU (1) RU2275913C2 (en)
TW (1) TWI313609B (en)
UA (1) UA75450C2 (en)
WO (1) WO2003015826A1 (en)
ZA (1) ZA200400917B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (en) * 2007-03-29 2009-07-03 Proteins & Peptides Man DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS
ES2672201T3 (en) 2008-07-16 2018-06-13 Children's Medical Center Corporation Imitation device of organs with microchannels and methods of use
KR101970634B1 (en) 2011-06-02 2019-04-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods and uses for ex vivo tissue culture systems
PL221351B1 (en) 2012-03-14 2016-03-31 Politechnika Warszawska Method for obtaining polysaccharide nanoparticles
ES2671644T3 (en) * 2012-10-11 2018-06-07 Daiichi Sankyo Company, Limited Antibody Conjugate - Drug
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2015115091A1 (en) 2014-01-31 2015-08-06 第一三共株式会社 Anti-her2 antibody-drug conjugate
TWI718144B (en) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TW201828993A (en) 2016-12-12 2018-08-16 日商第一三共股份有限公司 Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR102537651B1 (en) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 Anti-GPR20 Antibodies and Anti-GPR20 Antibody-Drug Conjugates
TW202330036A (en) 2017-05-15 2023-08-01 日商第一三共股份有限公司 Manufacturing method of antibody-drug conjugates
KR20200041993A (en) 2017-08-31 2020-04-22 다이이찌 산쿄 가부시키가이샤 Method for improved production of antibody-drug conjugates
CN117838881A (en) 2017-08-31 2024-04-09 第一三共株式会社 New method for preparing antibody-drug conjugate
CN117815404A (en) 2018-05-18 2024-04-05 第一三共株式会社 anti-MUC 1 antibody-drug conjugates
CN109481691A (en) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688931A (en) * 1993-02-26 1997-11-18 Drug Delivery System Institute, Ltd. Polysaccharide derivatives and drug carriers
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
WO1997038727A1 (en) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Medicament composite
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (en) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 Low contract photo-solidification cladding material, its prepn. method and use
EP1080732A4 (en) * 1998-05-22 2004-08-25 Daiichi Seiyaku Co Drug composites

Also Published As

Publication number Publication date
NO20041194L (en) 2004-03-19
BR0212036A (en) 2004-08-17
EP1418947A1 (en) 2004-05-19
NZ530947A (en) 2006-04-28
CN1545423A (en) 2004-11-10
AU2002328093B2 (en) 2005-05-05
HUP0401351A2 (en) 2004-12-28
CA2457056A1 (en) 2003-02-27
ZA200400917B (en) 2004-08-25
CA2457056C (en) 2008-07-22
RU2275913C2 (en) 2006-05-10
CN100372570C (en) 2008-03-05
IL160148A0 (en) 2004-07-25
PL368319A1 (en) 2005-03-21
WO2003015826A1 (en) 2003-02-27
RU2004108141A (en) 2005-04-20
HUP0401351A3 (en) 2011-02-28
KR20040027972A (en) 2004-04-01
TWI313609B (en) 2009-08-21
UA75450C2 (en) 2006-04-17
MXPA04001599A (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AR035137A1 (en) PHARMACEUTICAL COMPOSITION TO INHIBIT METASTASIS OR PREVENT RECURRENCE OF EVIL TUMOR
BR112019006816A8 (en) BENZO[B]THIOPHENE COMPOUNDS AS STING AGONISTS, PHARMACEUTICAL COMPOSITION AND THEIR USE
CY1116103T1 (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
ECSP10010254A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
UY30437A1 (en) QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C
ATE404536T1 (en) SUBSTITUTED QUINOLINE DERIVATIVES AS INHIBITORS OF MITOTIC KINESIN
BR0315547A (en) Quinoline derivatives as crth2 antagonists
AR061238A1 (en) HEPATITIS C PROTEASE INHIBITORS MACROCICLIC OXYLMYL COMPOUNDS
AR035885A1 (en) DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
ECSP077648A (en) MACROCICLIC TETRAZOLILS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
EE200100485A (en) Novel Compounds and Compositions as Protease Inhibitors
TW200700393A (en) Novel cis-2,4,5-triaryl-imidazolines
ECSP066424A (en) DERIVATIVES OF 2,4-DI- (IET) -ARIL-AMINO-PYRIMIDINE AS INHIBITORS OF ZAP-70 AND / OR SYK
TR200103186T2 (en) Quinoline derivatives as inhibitors of MEK enzymes
AR035365A1 (en) PEPTIDIC COMPOUND THAT INCLUDES AN INHIBITOR CENTER FOR THE METIONIN AMINOPEPTIDASE 2 (METAP-2) AND ITS USE TO PREPARE A MEDICINAL PRODUCT
HUP0105231A2 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents and medicaments containing the compounds
BRPI0313942C1 (en) benzimidazole derivatives useful as antiproliferative agents, their preparation processes, pharmaceutical composition comprising the same and uses of said compounds in the preparation of pharmaceutical compositions
EA201170607A1 (en) ACRYLAMID DERIVATIVES APPLICABLE AS INHIBITORS
CO5631443A2 (en) DERIVATIVES OF 7-ARIL-3,9-DIAZABICICLO (3.3.1) NON-6-ENO AND ITS USE AS RHENINE INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
UY30391A1 (en) HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND
EP3558317A1 (en) Combination chemotherapies
MX2010008109A (en) Difluorinated tripeptides as hcv serine protease inhibitors.
AR059113A1 (en) COMPOSITION FOR TOPICAL ADMINISTRATION
CO6270285A2 (en) DERIVATIVES OF 4 - [(4-AMINO-1, 3, 5-TRIAZIN-2-IL) AMINO] -N-ARILMETILCICLOALQUILCARBOXAMIDA
EA200702672A1 (en) INDOLAS DERIVATIVES OWN WITH ANTI-TUMOR ACTIVITY

Legal Events

Date Code Title Description
FB Suspension of granting procedure